Electronic health records have the potential to support outcome-based drug pricing, but are not yet capable of accurately tracking a drug's role in improving patient outcomes, such as reducing readmissions, Reuters reports. The article, which interviewed the CEOs of drug manufacturers Novartis and Roche, notes that the current pay-per-pill approach will eventually be unsustainable from a cost standpoint.
Other barriers to outcome-based drug pricing include the need for a large IT infrastructure to support it, medical privacy concerns and resistance from doctors who fear an increased administration burden and bureaucracy. Article